Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine + zoledronic acid versus capecitabine alone for first-line advanced triple-negative breast cancer without bone metastasis
ChiCTR-OIC-17012236Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Sep 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine and zoledronic acid in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Size of the lesions. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
capecitabinezoledronic acid
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on ChiCTR-OIC-17012236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17012236.